Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ICARES MedicusROCO:6612 +3.00%87 Debt-to-EBITDA is 2.19 as of Jun. 2026, which is 606% above its 10-year median of 0.31. GuruFocus rates ROCO:6612 with a GF Score™ of 87/100 and a GF Value™ of NT$153.08 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 471 Medical Devices & Instruments companies, ICARES Medicus ranks worse than 67.94% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for ICARES Medicus's Debt-to-EBITDA or its related term are showing as below:
ROCO:6612'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03 Med: 0.31 Max: 3.61
Current: 2.78
During the past 13 years, the highest Debt-to-EBITDA Ratio of ICARES Medicus was 3.61. The lowest was 0.03. And the median was 0.31.
ROCO:6612's Debt-to-EBITDA is ranked worse than 67.94% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs ROCO:6612: 2.78
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
ICARES Medicus Debt-to-EBITDA Related Terms
ICARES Medicus Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for ICARES Medicus's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6612 vs ISRG, BDX, RMD: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, ICARES Medicus's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICARES Medicus Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICARES Medicus's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ICARES Medicus's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
ICARES Medicus (ROCO:6612) has a Debt-to-EBITDA of 2.19 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on ICARES Medicus. This is 606% above median its historical median of 0.31. Over the past decade, ICARES Medicus' Debt-to-EBITDA has ranged from 0.03 to 3.61. According to the industry distribution chart, ICARES Medicus ranks #320 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 67.9%.
Is ICARES Medicus' Debt-to-EBITDA too high?
ICARES Medicus' current Debt-to-EBITDA of 2.19 is 606% above median its 10-year median of 0.31. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 3.61. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.63. ICARES Medicus' value of 2.19 is 34.4% above this industry median. Based on the distribution chart, ICARES Medicus ranks #320 out of 471 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, ICARES Medicus has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ICARES Medicus' Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, ICARES Medicus ranks #320 out of 471 companies for Debt-to-EBITDA. This places ICARES Medicus in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. ICARES Medicus' value of 2.19 is 34.4% above this benchmark. Historically, ICARES Medicus' own Debt-to-EBITDA has ranged from 0.03 to 3.61 over the past decade. While the company's 10-year median is 0.31 vs. the industry median of 1.63, ICARES Medicus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ICARES Medicus's current Debt-to-EBITDA of 2.19 is 34.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on ICARES Medicus. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ICARES Medicus's current Debt-to-EBITDA is 2.19, which is 606% above median its own 10-year median of 0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICARES Medicus stock overvalued right now?
Based on GuruFocus' analysis, ICARES Medicus (ROCO:6612) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$153.08, compared to a current price of NT$72.10 — trading 52.9% below its estimated fair value. The current Debt-to-EBITDA is 2.19, which is 606% above median its 10-year median of 0.31 and 34.4% above the Medical Devices & Instruments industry median of 1.63. ICARES Medicus' overall GF Score™ is 87/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For ICARES Medicus (ROCO:6612), the current Debt-to-EBITDA is 2.19 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ICARES Medicus (ROCO:6612) Overvalued in 2026?
Based on GuruFocus' analysis, ICARES Medicus stock appears to be undervalued.
The current stock price of NT$72.10 is trading 52.9% below its estimated GF Value™ of NT$153.08.
GuruFocus considers ICARES Medicus to be Significantly Undervalued.
Key valuation signals for ROCO:6612:
Debt-to-EBITDA: 2.19 (606% above median its 10-year median of 0.31)
GF Value™: NT$153.08 vs. price of NT$72.10 (52.9% below fair value)
Industry Position: 34.4% above the Medical Devices & Instruments median (#320 of 471)
No single metric tells the full story. See the ROCO:6612 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ICARES Medicus Inc is engaged in providing high-grade nanomedical lubricious coatings and various surface treatments for implantable or interventional medical devices. In addition, it also designs, develops, manufactures, and sells intraocular lenses and nanomedical devices. The company's operating segments are Europe and America, which derive maximum revenue, China, and R.O.C. Geographically, it generates maximum revenue from the United States, followed by Taiwan, Spain, England, Japan, China, Germany, and other countries.
87GF Score
Get the complete analysis for ROCO:6612
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6612 has been successfully added to your 
